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1. INTRODUCTION {#dom13115-sec-0005}
===============

People with type 2 diabetes mellitus (T2DM) frequently experience micro‐ and macrovascular complications.[1](#dom13115-bib-0001){ref-type="ref"} These complications can lead to lower extremity amputation, one of the severe consequences of advanced diabetes.[2](#dom13115-bib-0002){ref-type="ref"} Patients with diabetes account for the majority of all cases of lower extremity amputation, with the rate of lower extremity amputation for patients with diabetes reported to be ∼1.5 to 5.0 per 1000 patient‐years.[3](#dom13115-bib-0003){ref-type="ref"}, [4](#dom13115-bib-0004){ref-type="ref"} In addition to diabetes itself, many comorbid conditions can contribute to the increased risk of chronic lower extremity ulceration, including diabetic peripheral neuropathy, vascular insufficiency and infection, all of which can precede a traumatic lower extremity amputation.[5](#dom13115-bib-0005){ref-type="ref"} Additionally, cardiovascular (CV) disease is a well‐documented risk factor for amputation in patients with T2DM.[6](#dom13115-bib-0006){ref-type="ref"}, [7](#dom13115-bib-0007){ref-type="ref"}

Optimal glycaemic control is associated with reduced risk of lower extremity amputation and other microvascular events, and is the cornerstone of diabetes therapy.[8](#dom13115-bib-0008){ref-type="ref"}, [9](#dom13115-bib-0009){ref-type="ref"} Sodium glucose co‐transporter 2 (SGLT2) inhibitors reduce plasma glucose by increasing the renal threshold for glucose, leading to increased urinary glucose excretion and a mild osmotic diuresis that may be associated with a reduction in intravascular volume.[10](#dom13115-bib-0010){ref-type="ref"}, [11](#dom13115-bib-0011){ref-type="ref"} Canagliflozin, dapagliflozin and empagliflozin are SGLT2 inhibitors approved for the treatment of T2DM in the USA.[12](#dom13115-bib-0012){ref-type="ref"}, [13](#dom13115-bib-0013){ref-type="ref"}, [14](#dom13115-bib-0014){ref-type="ref"}

Analysis of data from the CANVAS Program, which comprises 2 large CV outcomes trials of canagliflozin in patients with T2DM and a history or high risk of CV disease, the CANagliflozin cardioVascular Assessment Study (CANVAS) and CANVAS‐Renal (CANVAS‐R), showed an increased risk of lower extremity amputation, mainly of the toe and middle of the foot, with canagliflozin. In the CANVAS Program, amputation rates were 6.3 and 3.4 per 1000 person‐years with canagliflozin and placebo, respectively.[15](#dom13115-bib-0015){ref-type="ref"} The amputation rates were 5.9 and 2.8 per 1000 person‐years with canagliflozin and placebo, respectively, in CANVAS, and 7.5 and 4.2 per 1000 person‐years with canagliflozin and placebo, respectively, in CANVAS‐R.[16](#dom13115-bib-0016){ref-type="ref"} The US Food and Drug Administration issued a Drug Safety Communication based on these findings, and the US prescribing information has been modified to reflect an increased risk of amputation in patients with high risk of CV events or a history of CV events.[16](#dom13115-bib-0016){ref-type="ref"}, [17](#dom13115-bib-0017){ref-type="ref"} No imbalance in the risk of amputation in patients with high CV risk was reported in the completed EMPA‐REG OUTCOME study of empagliflozin, although that trial did not systematically collect adequate data to confirm or refute this risk.[18](#dom13115-bib-0018){ref-type="ref"} The Dapagliflozin Effect on CardiovascuLAR Events (DECLARE) trial, a large‐scale CV outcomes trial of dapagliflozin, is ongoing and is now required by the European Medicines Agency to collect data systematically on and report amputation events.[19](#dom13115-bib-0019){ref-type="ref"}

Although an amputation imbalance was observed in the CANVAS Program, no such imbalance was observed across the canagliflozin phase III and IV study programme, which included more than 8100 patients with T2DM at low CV risk. In the non‐CANVAS canagliflozin studies, the incidence rates of amputation were 0.5 and 2.2 per 1000 person‐years with canagliflozin and placebo, respectively, and the relative risk of amputation events was 0.23 (95% confidence interval \[CI\] 0.06, 0.89; data on file). A total of 3 patients had amputations in the canagliflozin group and 7 in the control placebo group among the more than 8100 patients studied; thus, the analysis lacked power to provide definitive evidence regarding amputation risk with canagliflozin. To evaluate the risk of amputation in a general population of patients with T2DM in routine clinical practice, the present retrospective study used the Truven MarketScan Commercial Claims and Encounters (CCAE) database to examine the incidence of below‐knee lower extremity (BKLE) amputation among new users of any SGLT2 inhibitor (canagliflozin, dapagliflozin or empagliflozin), canagliflozin only or a non‐SGLT2 inhibitor antihyperglycaemic agent (AHA).

2. MATERIALS AND METHODS {#dom13115-sec-0006}
========================

This was an observational, retrospective, new‐user cohort study.

2.1. Data source {#dom13115-sec-0007}
----------------

Eligible patients were identified using the Truven MarketScan CCAE database, a large administrative health claims database for active employees, early retirees and their dependents, insured by employer‐sponsored plans in the USA. All study variables were based on insurance claims.

2.2. Sample size {#dom13115-sec-0008}
----------------

Comparative analysis was undertaken to formally statistically compare the hazards of BKLE amputation between new users of canagliflozin and non‐SGLT2 inhibitor AHAs based on an exposure propensity score (EPS)‐matched cohort. It was estimated that 191 BKLE amputation events in the combined cohort would be required to detect a relative risk of 1.5 with 80% power and a type I error rate of 0.05 (2‐sided). The database was assessed with each data refresh (every 6 months) until a total of \~191 events had accrued. Procedure codes for amputation events used in this analysis are listed in Table [S1](#dom13115-supitem-0001){ref-type="supplementary-material"}. Patients with no history of BKLE amputation and ≥1 day at risk were eligible for inclusion in the comparative analysis.

2.3. New‐user cohort creation {#dom13115-sec-0009}
-----------------------------

Eligible patients were required to have ≥365 days of observation prior to index, had been diagnosed with T2DM, and were newly exposed to a SGLT2 inhibitor (canagliflozin, dapagliflozin or empagliflozin) or a non‐SGLT2 inhibitor AHA (non‐metformin) between April 1, 2013 and October 31, 2016. Non‐SGLT2 inhibitor AHAs included dipeptidyl peptidase‐4 (DPP‐4) inhibitors (alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin), glucagon‐like peptide‐1 (GLP‐1) agonists (albiglutide, dulaglutide, exenatide, liraglutide and lixisenatide), thiazolidinediones (pioglitazone, rosiglitazone and troglitazone), sulfphonylureas (SU; glipizide, glyburide, glimepiride, chlorpropamide, tolazamide, tolbutamide and acetohexamide), insulin, and other AHAs (acarbose, bromocriptine, miglitol, nateglinide and repaglinide). Patients in the new‐user cohort were not exposed to the index drug during the baseline period, but may have been exposed to other AHA therapies (eg, multiple add‐on therapies). For example, new users of SGLT2 inhibitors were not exposed to another drug in the SGLT2 inhibitor class over the baseline period, but could have been exposed to another AHA or combination of several other AHAs (eg, metformin or metformin + SU). Similarly, new users of non‐SGLT2 inhibitors (eg, new users of DPP‐4 inhibitors) could not have been exposed either to an SGLT2 inhibitor or a DPP‐4 inhibitor during the baseline period, but could have been exposed to another AHA or a combination of several other AHAs (eg, metformin or metformin + SU). The cohort start date (ie, index date) was defined by the date of first index exposure in the study period. Patients with a history of type 1 diabetes, secondary diabetes prior to or on the exposure date or previous exposure to any SGLT2 inhibitors within the observation period were excluded from this study.

The incidence of BKLE amputation was described separately for patients with established CV disease and those without established CV disease (ie, based on baseline CV disease status). Because the CCAE database does not reflect a random sample of a general population, these incidence calculations are direct observations, and CIs are not provided. Established CV disease was defined as any record of a diagnosis (cerebrovascular disease, myocardial infarction or peripheral vascular disease) or a procedure (coronary artery bypass graft, percutaneous coronary intervention or peripheral revascularization) during the baseline period (Table [S2](#dom13115-supitem-0001){ref-type="supplementary-material"}).

2.4. Cohort follow‐up {#dom13115-sec-0010}
---------------------

Patients were followed from the index date until the end of their observation time, regardless of whether they discontinued, switched or augmented treatment (ie, intent‐to‐treat approach). The primary outcome was the incident case of BKLE amputation, as defined by observing an associated procedure code in the outpatient or inpatient medical service claims between the index date and the end of the observation period.

2.5. Propensity score estimation and matching {#dom13115-sec-0011}
---------------------------------------------

We used EPS matching to reduce potential confounding by imbalanced baseline covariates; new users of canagliflozin were matched 1:1 to new users of non‐SGLT2 inhibitor AHAs. Large‐scale EPS was estimated using regularized logistic regression models,[20](#dom13115-bib-0020){ref-type="ref"} with the dependent variable being canagliflozin new user, and independent variables being the baseline confounders over the 12 months prior to the exposure index date. To avoid over‐fitting models and to accommodate a large number of predictors, the regularized logistic regression model was fit using a cyclic coordinate descending method with L~1~ penalty (ie, least absolute shrinkage and selection operator).[21](#dom13115-bib-0021){ref-type="ref"} The optimal regularization hyper‐parameter was estimated using 10‐fold cross‐validation. A conventional greedy algorithm with nearest‐neighbour matching minimizing the absolute difference between EPS was used for matching.[22](#dom13115-bib-0022){ref-type="ref"} The maximum matching caliper of the EPS (on the logit scale) was 20% of the standard deviation of the logit of the EPS.[23](#dom13115-bib-0023){ref-type="ref"} Standardized differences were tabulated across potential confounders to evaluate the matching effectiveness in achieving baseline covariate balance.[24](#dom13115-bib-0024){ref-type="ref"}

2.6. Statistical analyses {#dom13115-sec-0012}
-------------------------

### 2.6.1. Descriptive summary {#dom13115-sec-0013}

Crude incidence rates of BKLE amputation were estimated as the number of first BKLE amputation cases divided by the total at‐risk follow‐up time, and reported per 1000 person‐years at risk, for patients treated with canagliflozin, dapagliflozin, empagliflozin, any SGLT2 inhibitor, and non‐SGLT2 inhibitor AHAs, which were further stratified by CV disease status.

### 2.6.2. Comparative analysis {#dom13115-sec-0014}

A comparative analysis was performed using the conditional Cox proportional hazards model. While formal statistical comparisons were based on EPS‐matched cohorts, residual confounding might still be present; therefore, negative controls were used to perform empirical calibration to correct *P* values generated by the conditional Cox proportional hazards model to further control for random and systematic errors.[25](#dom13115-bib-0025){ref-type="ref"}, [26](#dom13115-bib-0026){ref-type="ref"}, [27](#dom13115-bib-0027){ref-type="ref"} Both uncalibrated and calibrated *P* values are presented. Kaplan--Meier plots were generated for the risk of BKLE amputation over time in the EPS‐matched new users of canagliflozin and non‐SGLT2 inhibitor AHAs.

### 2.6.3. Sensitivity analysis {#dom13115-sec-0015}

A sensitivity analysis was performed that compared the risk of amputation between new users of canagliflozin who had prior metformin use and no prior DPP‐4 inhibitor or GLP‐1 agonist use vs new users of DPP‐4 inhibitors or GLP‐1 agonists who had prior metformin use and no prior SGLT2 inhibitor use.

3. RESULTS {#dom13115-sec-0016}
==========

3.1. Study population {#dom13115-sec-0017}
---------------------

Between April 1, 2013 and October 31, 2016, there were a total of 119 567 new users of SGLT2 inhibitors with 140 145 person‐years at risk and 226 623 new users of non‐SGLT2 inhibitor AHAs with 283 406 person‐years at risk (Table [1](#dom13115-tbl-0001){ref-type="table-wrap"}). Of the new users of SGLT2 inhibitors, 73 024 were new users of canagliflozin with a total of 95 422 person‐years at risk. A total of 22% of new users of SGLT2 inhibitors (22% of those treated with canagliflozin) and 21% of new users of non‐SGLT2 inhibitor AHAs had established CV disease at baseline.

###### 

Crude incidence rate of BKLE amputation from the Truven MarketScan CCAE database

  New users cohort          Number of exposed persons   Persons with amputation before exposure   Person‐years at risk   Persons with BKLE amputation post‐exposure   Incidence rate, per 1000 person‐years
  ------------------------- --------------------------- ----------------------------------------- ---------------------- -------------------------------------------- ---------------------------------------
  **Overall**                                                                                                                                                         
  SGLT2 inhibitors          119 567                     225                                       140 145                171                                          1.22
  Canagliflozin             73 024                      139                                       95 422                 120                                          1.26
  Dapagliflozin             39 117                      76                                        38 541                 37                                           0.96
  Empagliflozin             24 433                      55                                        17 930                 25                                           1.39
  Non‐SGLT2 inhibitor AHA   226 623                     722                                       283 406                530                                          1.87
  **High CV risk**                                                                                                                                                    
  SGLT2 inhibitors          25 781                      120                                       30 050                 61                                           2.03
  Canagliflozin             15 850                      75                                        20 594                 41                                           1.99
  Dapagliflozin             8045                        46                                        7829                   10                                           1.28
  Empagliflozin             5568                        22                                        4098                   14                                           3.42
  Non‐SGLT2 inhibitor AHA   48 483                      357                                       58 903                 194                                          3.29
  **Non‐high CV risk**                                                                                                                                                
  SGLT2 inhibitors          93 786                      105                                       110 095                110                                          1.00
  Canagliflozin             57 174                      64                                        74 827                 79                                           1.06
  Dapagliflozin             31 072                      30                                        30 712                 27                                           0.88
  Empagliflozin             18 865                      33                                        13 831                 11                                           0.80
  Non‐SGLT2 inhibitor AHA   178 140                     365                                       224 503                336                                          1.50

3.2. Crude incidence of BKLE amputation {#dom13115-sec-0018}
---------------------------------------

The crude incidence of BKLE amputation in the overall SGLT2 inhibitor population was relatively low (1.22 per 1000 person‐years) and ranged from 0.96 per 1000 person‐years with dapagliflozin to 1.26 and 1.39 per 1000 person‐years with canagliflozin and empagliflozin, respectively. The incidence rate of BKLE amputation among new users of non‐SGLT2 inhibitor AHAs was 1.87 per 1000 person‐years.

A greater proportion of patients with established CV disease had a history of amputation before the index date compared with patients without established CV disease. The crude incidence rate of BKLE amputation in patients with established CV disease was 1.99, 1.28, 3.42, 2.03 and 3.29 per 1000 person‐years with canagliflozin, dapagliflozin, empagliflozin, all SGLT2 inhibitors and non‐SGLT2 inhibitor AHAs, respectively. For patients without established CV disease, the incidence rate of BKLE amputation was 1.06, 0.88, 0.80, 1.00 and 1.05 with canagliflozin, dapagliflozin, empagliflozin, all SGLT2 inhibitors and non‐SGLT2 inhibitor AHAs, respectively. The distribution of BKLE amputation incident cases by procedure code is shown in Table [S3](#dom13115-supitem-0001){ref-type="supplementary-material"}.

3.3. Comparative analysis {#dom13115-sec-0019}
-------------------------

Of the 72 797 users of canagliflozin and 225 627 users of non‐SGLT2 inhibitor AHAs with no history of BKLE amputation and ≥1 day at risk who were eligible for inclusion in the comparative analysis, 63 845 pairs were formed based on matching of EPS (Figure [1](#dom13115-fig-0001){ref-type="fig"}). All baseline characteristics were well balanced after EPS matching (Figure [2](#dom13115-fig-0002){ref-type="fig"}), and patient demographics (age and sex), key comorbid conditions (including CV disease) and medications of interest (eg, commonly reported in patients with T2DM) for the treatment cohorts are presented in Table [2](#dom13115-tbl-0002){ref-type="table-wrap"}. The median (interquartile range \[IQR\]) duration of index therapy was 0.43 (0.17, 0.94) years with canagliflozin and 0.33 (0.12, 0.79) years with non‐SGLT2 inhibitor AHAs. In comparison, the overall median (IQR) follow‐up time based on the intention‐to‐treat analysis was 1.27 (0.62, 1.88) years with canagliflozin and 1.04 (0.48, 1.89) years with non‐SGLT2 inhibitor AHAs. Prior to the index date, a greater percentage of new users of canagliflozin had prior or current treatment with various AHAs compared with new users of non‐SGLT2 inhibitor AHAs. By design, use of AHAs was not included in the EPS model; therefore, it was expected that an imbalance in the use of AHAs at baseline may remain after matching (Table [2](#dom13115-tbl-0002){ref-type="table-wrap"}). After the index date, 99 patients treated with canagliflozin and 87 patients treated with a non‐SGLT2 inhibitor AHA had a BKLE amputation event post exposure (incidence rate, 1.18 and 1.12 per 1000 person‐years, respectively). The hazard of an incident BKLE amputation event was not significantly different between groups (hazard ratio \[HR\] 0.98 \[95% CI 0.68, 1.41\]; *P* = .92, calibrated *P* = .95).

![Attrition diagram for the comparative analysis](DOM-20-582-g001){#dom13115-fig-0001}

![Diagnostics of EPS matching performance](DOM-20-582-g002){#dom13115-fig-0002}

###### 

Distribution of patient characteristics and baseline AHA use before and after EPS matching

                                                                                                                  Before matching   After matching                            
  -------------------------------------------------------------------------------------------------------------- ----------------- ---------------- ------- -------- -------- -------
  Number of distinct persons                                                                                          72 797           225 627               63 845   63 845  
  Mean age,[a](#dom13115-note-0003){ref-type="fn"} years                                                               53.3              52.8       0.06      53.2     53.3   0.01
  Standard deviation                                                                                                    8.0              9.0                  8.1      8.1    
  Sex[b](#dom13115-note-0004){ref-type="fn"}                                                                                                                                  
  Male                                                                                                                 55.1              55.6       −0.01     55.5     55.3   0.00
  Female                                                                                                               44.9              44.4       0.01      44.5     44.7   0.00
  Index year[b](#dom13115-note-0004){ref-type="fn"}                                                                                                                           
  2013                                                                                                                 12.6              25.7       −0.34     13.7     12.6   0.03
  2014                                                                                                                 34.9              32.3       0.06      35.1     35.2   0.00
  2015                                                                                                                 38.2              23.7       0.32      36.0     37.0   −0.02
  2016                                                                                                                 14.2              18.2       −0.11     15.2     15.2   0.00
  Comorbidities of interest[b](#dom13115-note-0004){ref-type="fn"} ^,^ [c](#dom13115-note-0005){ref-type="fn"}                                                                
  Congestive heart failure                                                                                              1.4              2.6        −0.08     1.4      1.4    0.00
  Cardiomyopathy                                                                                                        1.3              1.8        −0.04     1.2      1.3    0.00
  COPD                                                                                                                  2.4              3.4        −0.06     2.4      2.4    0.00
  Disorder due to T2DM                                                                                                 13.9              13.1       0.02      12.9     12.8   0.00
  Chronic liver disease                                                                                                 4.8              4.8        0.00      4.7      4.7    0.00
  Hyperlipidaemia                                                                                                      75.5              64.6       0.24      74.1     74.6   −0.01
  Essential hypertension                                                                                               72.6              66.4       0.13      71.4     71.8   −0.01
  Cerebrovascular disease                                                                                               1.7              2.4        −0.05     1.6      1.6    0.00
  Malignant neoplastic disease                                                                                          5.4              6.1        −0.03     5.3      5.4    −0.01
  Peripheral vascular disease                                                                                           8.5              8.6        0.00      8.1      8.2    0.00
  Rheumatoid arthritis                                                                                                  1.0              1.1        −0.01     1.0      1.0    0.00
  Renal impairment                                                                                                      3.2              6.4        −0.15     3.2      3.2    0.00
  Venous thrombosis                                                                                                     1.3              1.8        −0.04     1.3      1.3    0.00
  Pancreatitis                                                                                                          0.7              1.0        −0.03     0.7      0.6    0.01
  Obesity                                                                                                              21.8              19.6       0.06      21.0     21.2   0.00
  Medications of interest[b](#dom13115-note-0004){ref-type="fn"} ^,^ [d](#dom13115-note-0006){ref-type="fn"}                                                                  
  Agents acting on the renin‐angiotensin system                                                                        76.2              69.0       0.16      74.9     75.3   −0.01
  Calcium channel blockers                                                                                             66.1              61.3       0.10      65.2     65.8   −0.01
  β‐blocking agents                                                                                                    51.4              49.4       0.04      50.6     51.1   −0.01
  HMG‐CoA reductase inhibitors                                                                                         80.0              74.4       0.13      79.1     82.1   −0.08
  Diuretics                                                                                                            80.9              74.9       0.14      79.7     80.1   −0.01
  Drugs for acid‐related disorders                                                                                     55.3              53.2       0.04      54.3     54.6   −0.01
  Digoxin                                                                                                               0.5              0.7        −0.02     0.5      0.5    0.00
  Anti‐inflammatory and anti‐rheumatic products, non‐steroids                                                          46.1              43.0       0.06      45.0     45.4   −0.01
  Selective serotonin reuptake inhibitors                                                                              14.4              13.0       0.04      13.9     14.0   0.00
  AHA therapies[b](#dom13115-note-0004){ref-type="fn"} ^,^ [d](#dom13115-note-0006){ref-type="fn"}                                                                            
  Metformin                                                                                                            81.3              67.8       0.31      81.1     76.0   0.12
  DPP‐4 inhibitors                                                                                                     35.9              7.7        0.72      35.9     8.3    0.70
  GLP‐1 agonists                                                                                                        4.9              0.3        0.29      4.5      0.3    0.28
  Thiazolidinediones                                                                                                   10.0              3.2        0.28      9.8      3.7    0.25
  Sulphonylureas                                                                                                       40.4              14.7       0.60      40.5     15.2   0.59
  Insulins and analogues                                                                                                9.0              1.4        0.35      6.6      2.7    0.19
  Other AHAs[e](#dom13115-note-0007){ref-type="fn"}                                                                     2.4              0.6        0.15      2.2      0.6    0.13

Abbreviations: COPD, chronic obstructive pulmonary disease; ER, emergency room; HMG‐CoA, 3‐hydroxy‐3‐methylglutaryl coenzyme A.

Data are mean, except standardized difference.

Data are in %, except standardized difference.

Condition occurrence record for the concept or any of its descendants observed during 365 days on or prior to cohort index.

Drug era record for the concept or any of its descendants observed during 365 days on or prior to cohort index.

Including acarbose, bromocriptine, miglitol, nateglinide and repaglinide.

3.4. Sensitivity analysis {#dom13115-sec-0020}
-------------------------

The sensitivity analysis produced results that were consistent with the primary analysis. The cohorts were sufficiently comparable and passed diagnostics after EPS matching. The matched sample had 30 380 patients in each cohort, and there were 56 patients with BKLE amputation post‐exposure in the target population. The effect estimate was not significantly different between groups (HR 0.87 \[95% CI 0.52, 1.46\]; *P* = .60, calibrated *P* = .65). Full results of the sensitivity analysis are available on request.

4. DISCUSSION {#dom13115-sec-0021}
=============

This large, observational, retrospective study was based on real‐world patient data in an EPS‐matched population with an average age of \~53 years, where \~8% of patients had peripheral vascular disease, 3.2% had renal impairment, and 1.4% had congestive heart failure. In the present study, we found that the overall risk of incident BKLE amputation was relatively low and found no evidence that the risk differs between patients with T2DM who were new users of canagliflozin and those who were new users of non‐SGLT2 inhibitor AHAs.

The findings from this observational study should be interpreted within the context of the total available evidence. As described above, no imbalance in the risk of amputation was observed in the pooled non‐CANVAS phase III and IV trials of canagliflozin, which included patients with T2DM with an average age of \~57 years and a baseline estimated glomerular filtration rate (eGFR) reflecting normal renal function (\~86 mL/min/1.73 m^2^). In this pooled non‐CANVAS population, \~22% of patients had ≥1 microvascular complication and there was also a lower proportion of patients with established CV disease (6.6%) compared with the CANVAS Program (65%); however, the analysis of the risk of lower extremity amputation in the non‐CANVAS population was limited by a low number of observed events. The use of observational database studies allowed analysis of the risk of amputation with canagliflozin in a larger population. The present observational study identified a total of 186 incident BKLE amputation events in a combined cohort of 127 690 patients (\~10‐fold larger population than the CANVAS Program) not enriched for CV disease (22% of patients had established CV disease). Consistent with the results from the non‐CANVAS population, analysis of the EPS‐matched cohort also found no evidence of increased BKLE amputation with canagliflozin (HR 0.98 \[95% CI 0.68, 1.41\]). By contrast, in the CANVAS Program, which enrolled patients with T2DM and high CV risk, the incidence of non‐traumatic BKLE amputation was increased \~2‐fold.[15](#dom13115-bib-0015){ref-type="ref"} The observed difference in BKLE amputation risk in these analyses may be attributable to differences in the study populations, specifically with respect to CV risk; more studies are needed to investigate the risk of amputation in patients with high CV risk in a real‐world setting. Currently, the mechanism behind the increased risk of BKLE amputation with canagliflozin in patients with T2DM and high CV risk is not well understood, although volume depletion and the potential for reduced tissue perfusion (because of the mechanism of the pharmacological action associated with this class of drug) may have played a role.

The present study was strengthened by the use of a large patient database that provided information on real‐world experience and is representative of the US commercially insured population. Use of this large, detailed database also allowed balancing of potential confounders by EPS matching. In addition, the use of negative control outcomes enabled us to further assess and minimize the likelihood of unmeasured confounding and systematic error.

As with all observational research, the present study is subject to several potential limitations. In spite of the more than 10 000 baseline variables that were included as potential confounders in the calculation of EPS, there could be unmeasured and residual confounding in this study. For example, some data that may affect risk estimation were not available or mostly missing from insurance claims (eg, socio‐economic status, behavioural variables, reason for BKLE amputation, body weight, changes in HbA1c, and duration of diabetes and disease state). In addition, insurance claims databases were originally constructed for financial reimbursement for services rather than research purposes. As such, some recorded and coded claims data may not be accurate and complete, and could be confounded by financial incentives. Furthermore, it was noted that the rate of amputation in the present study was lower than the rate reported in the CANVAS Program; this may be attributable, in part, to differences in patient age, duration of T2DM and prevalence of CV disease at baseline. Because the database reflects the experience of a commercially insured population, most of the study patients were aged \<65 years, which may limit the study\'s generalizability to older patients (eg, a Medicare population). Finally, by design, use of AHAs at baseline was not included in the exposure propensity model, and some imbalance remained after EPS matching. Although patients treated with canagliflozin may have had higher baseline HbA1c or more difficulty achieving glycaemic control (owing to more add‐on AHA therapies at baseline), additional analyses based on negative controls suggest that this imbalance resulted in limited, if any, confounding or bias.

In the present study, a general population of patients with T2DM treated with canagliflozin and non‐SGLT2 inhibitor AHAs did not have a different risk of lower extremity amputation. Overall, these results, based on real‐world evidence, suggest that patients with T2DM and average risk of CV disease treated with canagliflozin have the same low risk of amputation as patients treated with non‐SGLT2 inhibitor AHAs.
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**Table S1.** Procedure Codes for Amputation Events.

**Table S2.** Condition and Procedure Codes for High CV Risk\*.

**Table S3.** Distribution of BKLE Amputation Procedures.

###### 

Click here for additional data file.
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